Recursion Announced Its Partnership With Enamine To Generate Screening Libraries With Insights From Recursion's Protein-Ligand Interaction Predictions Spanning Across Enamine's Library Of 36 Billion Compounds
Portfolio Pulse from Benzinga Newsdesk
Recursion Pharmaceuticals has partnered with Enamine to create screening libraries using Recursion's MatchMaker protein-ligand interaction predictions. These libraries will be designed from Enamine's vast library of 36 billion compounds, focusing on up to 100 biological targets. Enamine will have the option to sell these libraries to customers and will co-brand them under both Enamine and MatchMaker trademarks.
December 20, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Recursion Pharmaceuticals' partnership with Enamine to develop screening libraries could enhance its product offerings and potentially lead to revenue growth through sales by Enamine.
The partnership with Enamine allows Recursion to expand its product capabilities, which could be seen positively by investors. The use of Recursion's MatchMaker technology in designing compound libraries may lead to innovative products and potential revenue through Enamine's sales, thus likely having a positive short-term impact on RXRX's stock price.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80